Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 – a promising target for cancer immunotherapy

Laura Schäkel(University of Bonn), Christa E. Müller(University of Bonn), Salahuddin Mirza(University of Bonn), Jean Sévigny(Cegep de Sainte Foy), Riekje Winzer(Universität Hamburg), Riham M. Idris(University of Bonn), Haneen Al-Hroub(University of Bonn), Julie Pelletier(Université Laval), Vittoria Lopez(University of Bonn), Eva Tolosa(University Medical Center Hamburg-Eppendorf)
Journal for ImmunoTherapy of Cancer
August 1, 2022
Cited by 34


Related Papers